Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma that has come back or stopped responding to treatment, and who have previously been treated with three specific types of therapy: an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody treatment.
• People whose myeloma has either relapsed (came back more than 60 days after stopping a previous treatment) or is refractory (stopped responding within 60 days of stopping treatment, or showed less than 25% reduction in a key protein marker).
• People who have at least one area of myeloma that has grown outside the bone marrow or formed a tumour connected to a bone, as seen on a PET/CT scan or MRI — and where at least one of these areas has not previously been treated with radiation and could be treated with radiation as part of this trial.
• People whose blood counts meet minimum levels: haemoglobin at least 7 g/dL, platelets at least 50,000 per microlitre, and neutrophils (infection-fighting white blood cells) at least 750 per microlitre (supportive treatments such as transfusions are allowed if low counts are due to the myeloma itself).
• People whose liver and kidney function test results fall within acceptable ranges for this trial (confirm with trial site for exact values).
• People who are well enough to carry out basic daily activities, rated 2 or below on a standard medical fitness scale — or who are rated higher only because of myeloma-related pain or complications, with the expectation that their fitness level could improve to that range.
• People who are not able to become pregnant, or who agree to use at least one highly effective method of contraception until 6 months after the last dose of study treatment.
• People who can become pregnant must have a negative pregnancy blood test at the start of the study and agree to further pregnancy testing during the trial.

Who may not be able to join:

• People who have received certain recent treatments before starting this trial — including any experimental treatment within 14 days (or 5 half-lives, whichever is shorter), standard myeloma drugs (IMiDs, PIs, anti-CD38 antibodies, or chemotherapy) within 7 days, a stem cell transplant using their own cells within 12 weeks, a donor stem cell transplant within 6 months, major surgery within 2 weeks, or who have had a stroke within the past 6 months.
• People with certain other blood or plasma cell conditions, including Waldenström's macroglobulinaemia, POEMS syndrome, amyloidosis, or active plasma cell leukaemia.
• People with a history of HIV infection.
• People with an active hepatitis B (HBV) infection that is not controlled despite antiviral medication.
• People with serious, uncontrolled conditions affecting the heart, lungs, digestive system, liver, kidneys, or brain that are not caused by myeloma and that the trial doctor determines make this type of treatment unsuitable.
• People with ongoing or recurring infections that are not under control.
• People with an autoimmune disease that requires ongoing systemic treatment, unless it is managed with low-dose steroids equivalent to 10 mg per day or less of prednisone.
• People with severely disabling mental health conditions, substance misuse (alcohol or drugs), dementia, or significantly altered mental state.
• People who have had another active cancer within the past 5 years that carries more than a minimal risk of returning (hormonal therapies for breast or prostate cancer are excepted).
• People with a condition called myelodysplastic syndrome (MDS), a disorder affecting blood cell production in the bone marrow.
• People for whom, in the trial doctor's judgement, participation would not be in their best interest, or who have any condition that could affect their ability to safely receive treatment or to understand and agree to the trial requirements.
• People with a known history of serious allergic reactions to medications that are chemically or biologically similar to the study drug (Elranatamab) or other drugs used in this trial.
• People with a history of not following recommended medical treatments.

Important: Always verify eligibility with the trial site directly before applying.